Triple-negative breast cancer (TNBC) accounts for 15%–20% of all breast cancers and is characterized by a lack of specific molecular biomarkers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [1]. Here, ERBB2 is linked to breast carcinoma.